S1PR1 and neoplasm: According to these observations, a potential of S1PR1 as an immune-oncology drug target by reducing intratumoral accumulation of Tregs and pro-tumor cytokine secretion by macrophages resulting in reduced tumor growth and metastasis is prominently discussed in the literature.